<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604198</url>
  </required_header>
  <id_info>
    <org_study_id>CORT125134-452</org_study_id>
    <nct_id>NCT03604198</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome</brief_title>
  <official_title>An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension study to evaluate the long-term safety of relacorilant in&#xD;
      patients with endogenous Cushing syndrome who successfully completed participation in a&#xD;
      Corcept-sponsored study of relacorilant and may benefit from continuing treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to allow continued therapy with relacorilant, a potent, selective&#xD;
      glucocorticoid receptor (GR) antagonist in patients who have successfully completed&#xD;
      participation of a Corcept-sponsored study of relacorilant (referred to as the &quot;parent&quot;&#xD;
      study). Patients may qualify to enter this extension study if they complete their last&#xD;
      treatment visit in their parent study and in the Investigator's opinion will benefit from&#xD;
      continued treatment.&#xD;
&#xD;
      Once-daily dosing with relacorilant may continue for patients who receive clinical benefits&#xD;
      (as judged by the Investigator) until relacorilant is commercially or otherwise available or&#xD;
      the study is stopped by the Sponsor. A patient's dose may be maintained, reduced, or&#xD;
      increased based on individual response and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-emergent adverse events (TEAEs)as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baseline as measured by glycated hemoglobin(HbA1c) and insulin resistance in patients with diabetes mellitus (DM) or glucose intolerance at Baseline in the parent study</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baseline as measured by systolic and diastolic blood pressure (BP) by ambulatory BP measurements (ABPM) in patients with uncontrolled hypertension (HTN) at Baseline in the parent study and in patients with controlled HTN taking at least one anti-HTN medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baseline in weight as measured by Kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baseline in waist circumference measured in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baselinein quality-of-life based on Cushing quality of life questionnaire 0 (worst) to 100 (best)</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term benefit of relacorilant</measure>
    <time_frame>36 months</time_frame>
    <description>Changes from Baseline in hypthalamic-pituitary-adrenal (HPA) axis markers (Plasma ACTH and Fasting Cortisol) and Sex steroid hormone (testosterone and estradiol)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cushing Syndrome</condition>
  <arm_group>
    <arm_group_label>relacorilant (CORT125134)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>relacorilant</intervention_name>
    <description>CORT125134 is supplied as capsules for oral dosing.</description>
    <arm_group_label>relacorilant (CORT125134)</arm_group_label>
    <other_name>CORT125134</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major Inclusion Criteria:&#xD;
&#xD;
               -  Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing&#xD;
                  syndrome with at least 80% compliance with the dosing schedule.&#xD;
&#xD;
               -  According to the Investigator's opinion will benefit from continuing treatment&#xD;
                  with relacorilant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major Exclusion Criteria:&#xD;
&#xD;
               -  Premature discontinuation from a relacorilant parent study.&#xD;
&#xD;
               -  Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism&#xD;
&#xD;
               -  Has poorly controlled hypertension&#xD;
&#xD;
               -  Has Stage â‰¥ 4 renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas G Moraitis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 097</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 087</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 033</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 061</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 190</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 074</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 047</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 070</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 059</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 035</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 072</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 188</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 079</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 073</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 093</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 189</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 026</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 131</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 023</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 088</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 083</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 095</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing Syndrome</keyword>
  <keyword>Cushing Disease</keyword>
  <keyword>Cushing</keyword>
  <keyword>Hypercortisolemia</keyword>
  <keyword>Cushingoid</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Impaired Glucose Intolerance</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Adrenal Corticotrophic Hormone (ACTH)</keyword>
  <keyword>Adrenocortical Carcinoma</keyword>
  <keyword>Primary Pigmented Nodular Adrenal Disease (PPNAD)</keyword>
  <keyword>Moon Facies</keyword>
  <keyword>Dorsocervical Fat Pad</keyword>
  <keyword>Adrenal Adenoma</keyword>
  <keyword>Adrenal Carcinoma</keyword>
  <keyword>Adrenal Autonomy</keyword>
  <keyword>Cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

